Molecular cancer prevention: Current status and future directions
Open Access
- 18 August 2015
- journal article
- review article
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 65 (5) , 345-383
Abstract
Answer questions and earn CME/CNE The heterogeneity and complexity of advanced cancers strongly support the rationale for an enhanced focus on molecular prevention as a priority strategy to reduce the burden of cancer. Molecular prevention encompasses traditional chemopreventive agents as well as vaccinations and therapeutic approaches to cancer‐predisposing conditions. Despite challenges to the field, we now have refined insights into cancer etiology and early pathogenesis; successful risk assessment and new risk models; agents with broad preventive efficacy (eg, aspirin) in common chronic diseases, including cancer; and a successful track record of more than 10 agents approved by the US Food and Drug Administration for the treatment of precancerous lesions or cancer risk reduction. The development of molecular preventive agents does not differ significantly from the development of therapies for advanced cancers, yet it has unique challenges and special considerations given that it most often involves healthy or asymptomatic individuals. Agents, biomarkers, cohorts, overall design, and endpoints are key determinants of molecular preventive trials, as with therapeutic trials, although distinctions exist for each within the preventive setting. Progress in the development and evolution of molecular preventive agents has been steadier in some organ systems, such as breast and skin, than in others. In order for molecular prevention to be fully realized as an effective strategy, several challenges to the field must be addressed. Here, the authors provide a brief overview of the context for and special considerations of molecular prevention along with a discussion of the results from major randomized controlled trials. CA Cancer J Clin 2015;65:345–383. © 2015 American Cancer Society .Keywords
Funding Information
- MD Anderson Cancer Center (5P30CA016672-37)
- University of California San Diego Moores Cancer Center (3P30CA023100-28)
- National Institutes of Health (N01, R01)
This publication has 306 references indexed in Scilit:
- Maintenance Bacillus Calmette-Guérin Treatment of Non–muscle-invasive Bladder Cancer: A Critical Evaluation of the EvidenceEuropean Urology, 2013
- Randomized controlled trial of acitretin versus placebo in patients at high‐risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)Cancer, 2011
- Persistence of Cardiovascular Risk After Rofecoxib DiscontinuationArchives of internal medicine (1960), 2010
- Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breastCancer, 2010
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other CancersJAMA, 2009
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002